Ajinomoto Pharmaceuticals Obtained the Marketing Approval of Valsartan–Cilnidipine Combination Tablets “ATEDIO® Tab.” in Japan

Ajinomoto Pharmaceuticals Co., Ltd. (“Ajinomoto Pharmaceuticals”) (President, Takashi Nagamachi; Headquarters, Chuo-ku, Tokyo, Japan) has obtained as of March 24, 2014 the marketing approval of valsartan–cilnidipine combination tablets “ATEDIO® Tab.” (code: AJH801) indicated for treatment of hypertension in Japan market. Ajinomoto Pharmaceuticals has developed this product under a joint development with Mochida Pharmaceutical Co., Ltd. (President, Naoyuki Mochida; headquarters, Shinjuku-ku, Tokyo, Japan). Mochida Pharmaceutical Co., Ltd. will undertake the distribution of “ATEDIO® Tab.” after the marketing approval.

“ATEDIO® Tab.” is the first combination tablets of cilnidipine, a long-acting calcium channel blocker that blocks N-type calcium channel, and angiotensin II receptor antagonist in Japan. The combination between the agents of different action mechanisms is expected to exert good anti-hypertensive effects.

Cilnidipine (Product name: “ATELEC® Tab.”) blocks both L-type and N-type calcium channels and inhibits blood pressure elevation due to sympathetic nerve hyperactivity as well as suppresses heart rate increase that occurs when blood pressure falls. Valsartan is an angiotensin II receptor antagonist with stable antihypertensive effects and widely used in treatment of hypertension.

It is often the case with treatment of hypertension that target blood pressures cannot be achieved enough by use of a single treatment agent, and, thus, combination use of different agents that have different action mechanisms is common. In addition, there are a number of patients with hypertension who take other medicines concomitantly with antihypertensive agents. Ajinomoto Pharmaceuticals expects that “ATEDIO® Tab.” can increase the convenience in medication and this will contribute to treatment and increase of patient’s Quality of Life.

Ajinomoto Pharmaceuticals is committed to a healthier and better quality of life of each individual patient through practice of “For Your Quality Of Life” to realize wishes of patients and medical practitioners.

[Contact]
Corporate Planning Dept., Ajinomoto Pharmaceuticals Co., Ltd.
TEL: +81-(0)3-6280-9802